People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of the study is to assess whether RO7790121 can help patients achieve clinical remission, which means a significant reduction in disease activity, and an endoscopic response, which refers to visible improvements in the digestive tract as seen through an endoscope. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over time to see how well the treatment works in reducing symptoms and improving their condition.

Throughout the study, researchers will track various outcomes, such as the overall change in symptoms, the severity of symptoms, and the general well-being of participants. They will also monitor any adverse events, which are unwanted effects that might occur during the trial. The study aims to provide valuable information on the potential benefits and risks of using RO7790121 for treating Crohn’s Disease, helping to improve future treatment options for those affected by this condition.

The purpose of this study is to see how effective Plozasiran is at reducing triglyceride levels in people with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo and will be monitored over a period of 12 months. During this time, the study will measure changes in triglyceride levels and monitor for any side effects. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo.

Participants will receive regular injections and attend scheduled visits to track their progress. The study aims to provide valuable information on the safety and effectiveness of Plozasiran, which could lead to new treatment options for people with severe hypertriglyceridemia. This research is important for understanding how to better manage this condition and improve patient outcomes.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The treatment involves regular injections of either maridebart cafraglutide or placebo, given in addition to standard heart failure treatments that participants are already receiving. The study will monitor how the medication affects participants’ heart health, particularly focusing on heart failure events that require medical attention and heart-related deaths.

During the study, researchers will track various aspects of participants’ health, including their heart function and quality of life. They will use questionnaires to assess how participants are feeling and functioning in their daily activities. The study will also monitor other important heart-related events such as myocardial infarction (heart attack) and ischemic stroke.

The purpose of the study is to determine if Eloralintide is more effective than a placebo at helping to change body weight. During the study, participants will be assigned to receive either the active medication or a placebo once every week. The process is double-blind, meaning that neither the participants nor the researchers know who is receiving the actual drug or the inactive substance until the study is complete. Participants will be monitored over a period of time to observe changes in weight and to ensure safety.

The study compares the effects of different treatment options. One group may receive a combination of Obicetrapib and Ezetimibe in a single tablet, while another group receives Obicetrapib alone. Other participants may receive a placebo. Throughout the course of the study, participants will take these tablets daily to see how they influence various types of cholesterol and other related markers in the blood.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The purpose of the study is to see how well Tirzepatide works compared to Dulaglutide in reducing major cardiovascular events, such as heart attacks or strokes, in people with Type 2 Diabetes who are at high risk for heart problems. Participants in the study will receive either Tirzepatide or Dulaglutide, along with their usual diabetes care, to see which treatment is more effective in preventing these serious heart-related events.

The study will take place over a period of time, during which participants will receive regular injections of either Tirzepatide or Dulaglutide. The researchers will monitor the participants’ health to track any occurrences of heart-related events. The goal is to determine if Tirzepatide is not only as effective as Dulaglutide but also if it might be superior in preventing major cardiovascular events in people with Type 2 Diabetes.

The purpose of the study is to find out if ponsegromab can help people gain body weight, improve appetite-related symptoms, and see if it is safe to use. During the study, participants will receive either ponsegromab or placebo along with their regular chemotherapy treatment. The study will measure changes in body weight, appetite symptoms, physical activity levels, and body composition using CT scan or MRI imaging. The study will also look at how the cancer responds to treatment and track overall survival and quality of life measures. Participants will be monitored for side effects and any changes in their health throughout the study period.

The study will last for several years and includes regular visits where measurements will be taken at different time points, with an important assessment at week 12. The study also includes an open-label extension phase where participants may continue to receive ponsegromab. Throughout the study, doctors will check body weight, muscle mass, fat tissue, physical activity, fatigue levels, and overall well-being using questionnaires and physical measurements.

Tirzepatide is given as an injection under the skin using a pre-filled pen once a week. The study will compare people taking tirzepatide to people taking placebo to see if there is a difference in major health events. These events include death from any cause, heart attack that is not fatal, stroke that is not fatal, procedures to restore blood flow to the heart, or problems related to heart failure. The study is looking at whether tirzepatide can help prevent these serious health problems in people who are overweight or have obesity and also have heart disease or risk factors for heart disease such as smoking, abnormal levels of fats in the blood, high blood pressure, or kidney disease.

People in the study will continue taking the treatment for a period of time while doctors monitor their health and track whether any of these major health events occur. The study will measure how long it takes until the first occurrence of any of these serious health problems happens in people taking tirzepatide compared to those taking placebo. The treatment period can last up to 324 weeks.

The treatment will involve taking PF-07248144 tablets by mouth along with fulvestrant injections into the muscle. Some patients will receive this combination, while others will receive different standard treatments such as everolimus or exemestane. The purpose is to determine if the combination of PF-07248144 and fulvestrant works better than currently available treatments in stopping the cancer from growing.

The study will last for up to 24 months. During this time, patients will have regular check-ups to monitor their health and see how well the treatment is working. Doctors will use special scans to measure if tumors are shrinking, staying the same size, or growing. They will also keep track of any side effects that patients may experience during the treatment.

The main purpose of this study is to determine if Verekitug can reduce the number of COPD flare-ups (also called exacerbations) that patients experience. During these flare-ups, COPD symptoms become worse than usual, often requiring additional medical treatment. The study will involve patients who have already experienced such flare-ups in the past and are currently using standard COPD medications.

The treatment period will last for 108 weeks (approximately two years). Throughout the study, participants will receive regular injections of either Verekitug or placebo, while continuing their usual COPD medications. The study will monitor how well participants breathe, their quality of life, and any side effects they may experience. Blood samples will be taken to measure how the medication works in the body.

The purpose of this research is to evaluate how safe the medication is and how well patients tolerate it when used for a longer period. The medication is given as a subcutaneous injection (under the skin) using a pre-filled syringe. This is an open-label extension study, which means all participants will receive the actual medication, and it continues treatment for patients who completed an earlier study called Lp(a)HORIZON.

During the study, participants will receive regular doses of pelacarsen for up to 36 months. The maximum daily dose is 80 milligrams. The study will monitor participants’ health through regular check-ups and blood tests to ensure their safety while taking the medication. Researchers will track various health measurements and any side effects that may occur during the treatment period.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of the study is to see if the combination of Sigvotatug vedotin and pembrolizumab is better at treating NSCLC compared to using pembrolizumab alone. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. The study will monitor how long patients live and how long they remain free from cancer progression. The trial will also look at the safety of the treatments and any side effects that may occur.

Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effectiveness of the treatment. The trial aims to provide valuable information that could improve treatment options for people with advanced non-small cell lung cancer.

The purpose of the study is to evaluate how well participants tolerate the medication over an extended period. Participants who have already shown a response to the treatment in previous trials will continue to take zasocitinib in capsule form. The study will last for up to 108 weeks, during which time participants will be monitored for any side effects or changes in their health. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual drug.

Throughout the study, participants will have regular check-ups to assess their health, including monitoring vital signs and conducting laboratory tests. The study aims to gather information on the long-term effects of zasocitinib to better understand its safety and effectiveness in treating Ulcerative Colitis and Crohn’s Disease.

The purpose of the study is to evaluate the safety of BI 456906 in terms of heart health compared to a placebo. Participants will receive either the treatment or a placebo and will be monitored over time to see if there are any differences in the occurrence of heart-related events such as heart attacks, strokes, or heart failure. The study will also look at changes in body weight, blood pressure, and other health markers over a period of time.

Participants in the study will be followed for several weeks, with regular check-ups to monitor their health and any changes that occur. The study aims to provide valuable information on whether BI 456906 is a safe and effective treatment option for people with obesity and related health conditions. The results could help improve the management of obesity and its complications in the future.

The purpose of the study is to compare the effectiveness of a new medicine called PF-07220060 when used in combination with another drug called letrozole, against a group of medicines known as CDK4/6 inhibitors (which include abemaciclib, palbociclib, and ribociclib) also used with letrozole. Letrozole is a medication that helps to lower estrogen levels in the body, which can slow the growth of certain types of breast cancer. CDK4/6 inhibitors are a class of drugs that work by interfering with cancer cell division, potentially slowing down or stopping the growth of cancer.

Participants in the study will be randomly assigned to receive either the combination of PF-07220060 and letrozole or one of the CDK4/6 inhibitors with letrozole. The study will last for a period of up to 36 months, during which the progress of the disease will be closely monitored. The main goal is to see which treatment combination is more effective in delaying the progression of the cancer. This study is open to individuals over the age of 18 who have not received any prior systemic treatment for their advanced or metastatic breast cancer.

The purpose of the study is to determine if pelacarsen can reduce the risk of major heart-related events, such as heart attacks, strokes, and the need for urgent heart procedures, in people who already have cardiovascular disease. Participants in the study will receive either the pelacarsen treatment or a placebo. The study will monitor participants over a period to see how the treatment affects their health and the occurrence of these major events.

Throughout the study, participants will receive regular injections and will be closely monitored by healthcare professionals. The study will help researchers understand if lowering lipoprotein (a) with pelacarsen can provide significant benefits for people with cardiovascular disease. The results could lead to new treatment options for managing heart health in the future.

The purpose of the study is to evaluate whether Zasocitinib can help achieve clinical remission, which means reducing the symptoms of ulcerative colitis, by the 12th week of treatment. Participants in the study will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The trial will last for a total of 52 weeks, with the main focus on the first 12 weeks to assess the initial response to the treatment.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the effects of the treatment. These assessments will include evaluating symptoms such as stool frequency and rectal bleeding, as well as conducting endoscopic examinations to observe the condition of the colon. The study aims to provide valuable information on the potential benefits of Zasocitinib for individuals suffering from ulcerative colitis, with the hope of improving their quality of life.

The purpose of the study is to compare the new treatment combination to other therapies chosen by the study doctors. Participants will be randomly assigned to receive either the new treatment or one of the other therapies. The study will last for up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of their cancer. The study aims to see if the new treatment can help delay the progression of the disease.

Participants in the study will include adults over the age of 18 who have previously been treated with a type of medication known as a CDK 4/6 inhibitor, which is used to slow down the growth of cancer cells. The study will also look at how the new treatment affects overall survival, the response of the cancer to treatment, and the quality of life of participants. This research is important for finding new ways to manage and treat advanced breast cancer, offering hope for improved outcomes for patients in the future.

The trial investigates whether using semaglutide along with a lower dose of insulin can control blood sugar levels just as effectively as using a higher dose of insulin by itself. Both medications are given through subcutaneous injection (under the skin) using pre-filled injection pens. The semaglutide is given once weekly, while insulin glargine is administered once daily.

The study lasts for 40 weeks and involves measuring changes in HbA1c (a measure of average blood sugar levels over the past 2-3 months). Participants will receive either a combination of semaglutide with reduced insulin glargine or insulin glargine alone. The study also looks at changes in body weight and how satisfied participants are with their treatment.

The purpose of this research is to assess how well remibrutinib works over an extended period in patients who have already participated in previous studies of this medication. During the study, patients who showed improvement in their symptoms will either continue taking remibrutinib or switch to placebo. The researchers will monitor how long it takes for symptoms to return, if they do.

Throughout the study, participants may also receive other common treatments for their condition, including antihistamines (medications that reduce allergic symptoms) and corticosteroids (medications that reduce inflammation). The study will track any side effects that occur during the treatment period. The total duration of treatment may last up to 160 weeks, depending on the participant’s response to the medication.

The purpose of the study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with Hypertriglyceridemia. Participants in the study will receive either the Plozasiran injection or a placebo. The study will last for about 12 months, during which participants will have regular check-ups to monitor their triglyceride levels and overall health.

This study is conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure the results are unbiased. The main goal is to see if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to determine how many participants achieve a healthy triglyceride level by the end of the study.

The treatment involves receiving either Lutikizumab or placebo through subcutaneous injection (an injection under the skin). The medication being tested is a biotechnology product that aims to reduce the signs and symptoms of moderate to severe Hidradenitis Suppurativa. The study will assess how well the treatment works in both adults and adolescents who have had inadequate results with previous treatments.

The study will measure several aspects of the condition, including reduction in the number of inflammatory bumps and draining wounds, improvement in pain levels, and changes in quality of life. The treatment period will last for several months to properly evaluate the medication’s effectiveness. Throughout the study, participants will be closely monitored to ensure their safety and to track their response to the treatment.

Participants in the study will receive either XXB750 or a placebo over a period of 16 weeks. The study aims to find the best dose of XXB750 that can help reduce the levels of NT-proBNP, which is a marker used to assess heart failure severity. Patients will continue to receive their standard heart failure treatments, such as ACE inhibitors or ARBs, which are common medications used to manage heart failure symptoms.

The trial will monitor changes in NT-proBNP levels and assess any side effects or changes in health during the study period. This research is important to determine if XXB750 can be a beneficial addition to existing heart failure treatments, potentially improving the quality of life for those affected by this condition.

The purpose of the study is to evaluate how well the new combination inhaler improves lung function and reduces asthma attacks compared to the other treatments. Participants in the study will use the inhalers over a period of 24 to 52 weeks. During this time, they will visit the study center regularly for check-ups and assessments. The study will help determine if the new inhaler is more effective in managing asthma symptoms and preventing severe asthma attacks.

In addition to the inhalers, some participants may also use other medications like Salbutamol, which is a fast-acting inhaler used for quick relief of asthma symptoms, and Prednisolone, a tablet used to treat severe asthma attacks. The study aims to provide valuable information on the safety and effectiveness of the new inhaler combination for people with severe asthma.